TABLE 5.

Phase III randomised trials of PD-1 and PD-L1 inhibitors showing efficacy results and the technologies used for PD-L1 testing

	CheckMate 017 [ 83 ]		CheckMate 057 [ 84 ]		CheckMate 026 [ 87 ]		Keynote 010 [ 85 ]		Keynote 024 [ 86 ]		OAK [ 88 ]
Population	sNSCLC		nsNSCLC		PD-L1 ≥1%		PD-L1 ≥1%		PD-L1 ≥50%		NSCLC
Treatment line	≥Second-line		≥Second-line		First-line		≥Second-line		First-line		≥Second-line
Drug	Nivo	Doce	Nivo	Doce	Nivo	Chemo	Pembro	Doce	Pembro	Chemo	Atezo	Doce
ORR %	20	9	19	12	26.1	33.5	18	9	44.8	27.8	14	13
PFS months	3.5	2.8	2.3	4.2	4.2	5.9	3.9, 4.0#	4.0	10.3	6.0	2.8	4.0
Overall survival months	9.2	6.0	12.2	9.4	14.4	13.2	10.4, 12.7#	8.5	80.2%¶	72.4%¶	13.8	9.6
PD-L1 expression
Antibody	28-8		28-8		28-8		22C3		22C3		SP142
Platform manufacturer	Dako		Dako		Dako		Dako		Dako		Ventana
Analysed cells	Tumour cells		Tumour cells		Tumour cells		Tumour cells		Tumour cells		Tumour and immune cells
Thresholds	1%, 5%, 10%		1%, 5%, 10%		1%, 5%, 10%		1%, 50%		1%, 50%		Tumour: 1%, 5%, 50%; Immune: 1%, 5%, 10%
Sampling time	Pretreatment		Pretreatment		Pretreatment		Any		Pretreatment		Pretreatment
Preanalytic	Archival FFPE		Archival FFPE		Archival FFPE		Archival or new		Archival or new		Archival or new

ORR: objective response rate; PFS: progression-free survival; PD-L1: programmed cell death ligand 1; NSCLC: nonsmall cell lung cancer; Nivo: nivolumab; Doce: docetaxel; Chemo: chemotherapy; Pembro: pembrolizumab; Atezo: atezolizumab; FFPE: formalin-fixed paraffin-embedded. ^#: two doses of pembrolizumab were tested (2 mg·kg⁻¹ and 10 mg·kg⁻¹); ^¶: 6-month overall survival rate.